Celltrion, Inc. (KRX:068270)
South Korea · Delayed Price · Currency is KRW 201,500
-500 (-0.25%)
At close: Mar 20, 2026
Celltrion Revenue
Celltrion had revenue of 1.03T KRW in the quarter ending September 30, 2025, with 16.67% growth. This brings the company's revenue in the last twelve months to 3.90T, up 35.45% year-over-year. In the year 2024, Celltrion had annual revenue of 3.56T with 63.45% growth.
Revenue (ttm)
3.90T
Revenue Growth
+35.45%
P/S Ratio
10.62
Revenue / Employee
1.55B
Employees
2,680
Market Cap
44.21T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.56T | 1.38T | 63.45% |
| Dec 31, 2023 | 2.18T | -107.54B | -4.71% |
| Dec 31, 2022 | 2.28T | 390.57B | 20.63% |
| Dec 31, 2021 | 1.89T | 44.29B | 2.39% |
| Dec 31, 2020 | 1.85T | 720.66B | 63.86% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Samsung Epis Holdings | 3.02T |
| SK Biopharmaceuticals | 706.74B |
| PharmaResearch | 496.03B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| OliX Pharmaceuticals | 10.18B |
Celltrion News
- 4 days ago - Celltrion Enters Contract Manufacturing Agreement With Global Pharmaceutical Company - Nasdaq
- 4 days ago - Celltrion Announces Commercial Availability In US Of AVTOZMA SC, Tocilizumab Biosimilar - Nasdaq
- 4 weeks ago - Celltrion Reports Post-hoc Analysis From LIBERTY Studies - Nasdaq
- 3 months ago - FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR - Nasdaq
- 5 months ago - FDA Approves Celltrion's EYDENZELT, Biosimilar To EYLEA, For Multiple Retinal Conditions - Nasdaq
- 6 months ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India
- 6 months ago - Celltrion (CONI.F) Acquires Imclone Systems to Strengthen U.S. Presence - GuruFocus
- 11 months ago - Celltrion to Cancel $72 Million in Shares to Boost Shareholder Value - GuruFocus